The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A. 2005

Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium.

The coumarins represent a unique class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that were isolated from tropical plants. (+)-Calanolide A, the most potent compound of this class, selects for the T139I resistance mutation in HIV-1 reverse transcriptase (RT). Seven RTs mutated at amino acid position 139 (Ala, Lys, Tyr, Asp, Ile, Ser, and Gln) were constructed by site-directed mutagenesis. The mutant T139Q enzyme retained full catalytic activity compared with wild-type RT, whereas the mutant T139I, T139S, and T139A RTs retained only 85 to 50% of the activity. Mutant T139K, T139D, and T139Y RTs had seriously impaired catalytic activities. The mutations in the T139I and T139D RTs were shown to destabilize the RT heterodimer. (+)-Calanolide A lost inhibitory activity (up to 20-fold) against the mutant T139Y, T139Q, T139K, and T139I enzymes. All of the mutant enzymes retained marked susceptibility toward the other NNRTIs, including nevirapine, delavirdine, efavirenz, thiocarboxanilide UC-781, quinoxaline GW867420X, TSAO [[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)] derivatives, and the nucleoside inhibitor, ddGTP. The fact that the T139I RT 1) proved to be resistant to (+)-calanolide A, 2) represents a catalytically efficient enzyme, and 3) requires only a single transition point mutation (ACA-->ATA) in codon 139 seems to explain why mutant T139I RT virus strains, but not virus strains containing other amino acid changes at this position, predominantly emerge in cell cultures under (+)-calanolide A pressure.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D003374 Coumarins Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid. 1,2-Benzopyrone Derivatives,1,2-Benzopyrones,Coumarin Derivative,Coumarine,1,2-Benzo-Pyrones,Benzopyran-2-ones,Coumarin Derivatives,Coumarines,1,2 Benzo Pyrones,1,2 Benzopyrone Derivatives,1,2 Benzopyrones,Benzopyran 2 ones,Derivative, Coumarin,Derivatives, 1,2-Benzopyrone,Derivatives, Coumarin
D013912 Threonine An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins. L-Threonine,L Threonine
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D039681 Pyranocoumarins A type of COUMARINS with added pyran ring(s). Calanolides

Related Publications

Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
November 1996, The Journal of pharmacology and experimental therapeutics,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
February 1996, Biological chemistry Hoppe-Seyler,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
February 2002, Molecular pharmacology,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
April 1993, Molecular pharmacology,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
January 2004, Current topics in medicinal chemistry,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
January 1999, Antiviral therapy,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
July 1991, Proceedings of the National Academy of Sciences of the United States of America,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
January 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
June 1995, Biochemical and biophysical research communications,
Joeri Auwerx, and Fátima Rodríguez-Barrios, and Francesca Ceccherini-Silberstein, and Ana San-Félix, and Sonsoles Velázquez, and Erik De Clercq, and María-José Camarasa, and Carlo-Federico Perno, and Federico Gago, and Jan Balzarini
July 1989, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!